Carlsson S, Leapman M, Carroll P, Schröder F, Albertsen PC, Ilic D, Barry M, Frosch DL, Vickers A., BMC Med. 13:288. doi: 10.1186/s12916-015-0526-x., 2015 Nov 27
Investigators
Dominick L. Frosch, Ph.D., Director, PAMFRI
Abstract
Prostate cancer screening using prostate-specific antigen (PSA) is highly controversial.In this Q & A, Guest Editors for BMC Medicine's 'Spotlight on Prostate Cancer' article collection, Sigrid Carlsson and Andrew Vickers, invite some of the world's key opinion leaders to discuss who, and when, to screen for prostate cancer.
In response to the points of view from the invited experts, the Guest Editors summarize the experts' views and give their own personal opinions on PSA screening.